Anastrozole's Effects on Endometrial Health

Key Effects on Endometrial Tissue

• Anastrozole has minimal to no adverse effects on the endometrium and actually reverses tamoxifen-induced endometrial thickening, making it significantly safer than tamoxifen for endometrial health 1, 2
• Anastrozole demonstrates a "lesser effect" on endometrial tissue compared to tamoxifen, as shown in ATAC trial sub-protocols 2, 3, 4
• The ATAC trial documented significantly lower rates of endometrial carcinoma with anastrozole versus tamoxifen (0.2% vs. 0.8%; P = .02) 1, 5
• Anastrozole-treated patients experienced less vaginal bleeding (5.4% vs. 10.2%; P < .0001) and vaginal discharge (3.5% vs. 13.2%; P < .0001) compared to tamoxifen 5

Clinical Implications for Monitoring

• While anastrozole is safer for the endometrium, it carries increased risks for bone health (fracture rate 11.0% vs. 7.7% with tamoxifen) and musculoskeletal symptoms 5